
In non-small cell lung cancer (NSCLC), liver metastases (LM) exhibit inferior response to immunotherapy compared to primary lung lesions (PL). A cohort study involving 52 patients indicates a lower disease control rate in LM. Genomic landscapes are similar, but LM displays reduced immune activation and CD8+ T cell infiltration. These findings suggest the need for nuanced immunotherapy strategies for NSCLC patients with LM.
Like
Save
Share